-

Thermo Fisher Scientific Launches Thermo Scientific Glacios 3 Cryo-TEM

Equipped with the READY System to make structural biology research accessible to more labs

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduces a next-generation cryogenic transmission electron microscope (cryo-TEM) designed to help scientists understand structural biology with greater clarity — now accessible in more lab environments than ever before. The Thermo Scientific™ Glacios™ 3 Cryo-TEM offers researchers the next major advancement in 200 kV imaging and structural analysis.

Cryogenic electron microscopy (cryo-EM), an advanced technique of flash-freezing biomolecules to visualize them in their native states, enables the Glacios 3 Cryo-TEM to help researchers advance structure-based drug design. Cryo-EM has played a critical role in the development of RSV vaccines, GLP-1 therapies and ongoing research into potential HIV vaccines.

The Glacios 3 Cryo-TEM is equipped with the Thermo Scientific™ READY™ System, an integrated suite of technologies that mitigates vibrations and environmental disturbances, which enables installation in a broader range of laboratory spaces by significantly reducing lab renovation complexity. AI-powered software facilitates cryo-EM workflows to significantly increase throughput and data quality in comparison to traditional platforms.

New design features improve ease-of-use, increase productivity and enhance connectivity to transfer samples without contamination. These features provide access to a range of high-performance cryo-EM techniques, including single particle analysis, cryo-electron tomography (cryo-ET), and microcrystal electron diffraction (microED).

“The Glacios 3 Cryo-TEM opens the door for more institutions and researchers to harness the capabilities of cryo-EM, helping them tackle complex biological questions and enhance therapeutic development,” said Steve Reyntjens, Thermo Fisher Scientific vice president and general manager of life sciences. “This combination of advanced instrumentation and AI-powered workflows represents a step change in how scientists generate insights, which will accelerate the development of life-improving treatments.”

“When first presented with news of the Glacios 3, I was delighted to learn of the latest developments on its platform,” said Dr. Steve Smerdon, a professor of structural biology in the University of Birmingham Department of Cancer and Genomic Sciences. “The improvements to the enclosure are particularly impressive, as they will allow greater flexibility in choosing a site for the instrument with potentially substantial reductions in refurbishment and running costs.”

To learn more about the Glacios 3 cryo-TEM, please visit thermofisher.com/glacios.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Alex Runner, Thermo Fisher Scientific
336-259-4653
alex.runner@thermofisher.com

Jessika Parry, Greenough Communications
419-266-4016
jparry@greenoughagency.com

Thermo Fisher Scientific Inc.

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Alex Runner, Thermo Fisher Scientific
336-259-4653
alex.runner@thermofisher.com

Jessika Parry, Greenough Communications
419-266-4016
jparry@greenoughagency.com

More News From Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing....

Thermo Fisher Scientific Collaborates with The Michael J. Fox Foundation to Advance Proteomics-Enabled Parkinson’s Precision Medicine

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the completion of Olink Explore HT proteomic analysis of approximately 5,500 research samples from The Michael J. Fox Foundation’s (MJFF) landmark study, the Parkinson’s Precision Medicine Initiative (PPMI). The resulting data are now in PPMI’s data repository, where they are available to the global research community. The project creates a large-scale proteomics resource designe...

Thermo Fisher Scientific Presents End-to-End Diagnostic and Lab Solutions Addressing Unmet Clinical Needs at ADLM 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase its latest diagnostic innovations, recent regulatory milestones and expanded capabilities at the Association for Diagnostics & Laboratory Medicine Conference (ADLM), July 26-30, 2026, in Anaheim, Calif. Spanning specialty diagnostics, quality management and the full diagnostic continuum, Thermo Fisher’s presence at ADLM 2026 reflects its ongoing commitment to addressing unmet clinic...
Back to Newsroom